CGEM initiates NDA submission for zipalertinib plus chemotherapy
CGEN says it initiated a new drug application submission for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC under FDA Real-Time Oncology Review.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.